Biomarker Research for Response Prediction of TKI Treatment in Clear-Cell Renal Cell Carcinoma
Group Sylvie Rottey
Project 6
Biomarker Research for Response Prediction of TKI Treatment in Clear-Cell Renal Cell Carcinoma
Description
Tyrosine kinase inhibitors (TKI) are widely used in the treatment of metastatic clear-cell renal cell carcinoma (ccRCC), however the therapeutic response in these patients varies widely. At present, no validated biomarkers exist which could predict response, or lack thereof, in the individual patient. Since more and more treatment options are becoming available for patients with metastatic ccRCC the relevance of having such biomarkers available is increasing, in order to treat each patient with the most suitable therapy. This project consists of a retrospective cohort study including patients treated with a TKI as a first-line treatment. Archived tumor tissue obtained at diagnosis is being analyzed with full exome sequencing of both m-RNA and small-RNA. Correlations between RNA expression and/or mutations and response to treatment are being searched for. Findings will be related to the current literature in the field and/or validated in data from an external cohort. To obtain this, collaboration with other institutions is being established.
Funding Ageny
text
Contact
Sylvie Rottey; MD, PhD (Medical Oncology – Ghent University Hospital)
Jo Van Dorpe; MD, PhD (Pathology – Ghent University Hospital)
Brant Delafontaine; MD (Drug Research Unit Ghent – Ghent University Hospital)